Literature DB >> 30343483

Qualitative analysis of community pharmacists' opinions on their involvement in reducing potentially inappropriate prescribing.

Christina Raae Hansen1,2, Stephen Byrne3, Denis O'Mahony4,5, Patricia M Kearney6, Laura J Sahm3,7.   

Abstract

PURPOSE: Older people are at risk of potentially inappropriate prescribing (PIP) due to polypharmacy arising from multi-morbidity. Despite available explicit criteria to reduce PIP, it is highly prevalent. Whilst community pharmacists have the required knowledge to help reduce PIP, they are not currently engaged with the problem. This study explores the views of community pharmacists on their potential involvement in reducing PIP and determines the challenges to its implementation.
METHODS: Semi-structured interviews with pharmacists working in community pharmacies in Ireland. The theoretical domains framework (TDF) was used to develop the topic guide and to analyse the transcripts. Domains of highest relevance for PIP reduction were identified based on their frequency or whether the participants emphasised the impact of constructs within a domain. Local ethical approval was obtained.
RESULTS: Of 18 participants, 12 were female, median age was 30 years (IQR, 27-35) with a median of 6 years (IQR, 3-8) of experience. Seven TDF domains were identified as relevant to PIP reduction. Pharmacists were uncertain about their role in reducing PIP and reluctant to challenge physicians' prescribing decisions. Challenges pertained to the environment, knowledge, social influences, professional role and identity.
CONCLUSIONS: Pharmacists welcomed new responsibilities in reducing PIP as part of their daily practice but expressed a need for removal of social and environmental barriers as well as, provision of relevant guidelines and education about PIP. This study provides useful insights into the target domains for overcoming barriers of pharmacist involvement in reducing PIP.

Entities:  

Keywords:  Older patients; Pharmacist; Prescribing; Primary care; Qualitative

Mesh:

Year:  2018        PMID: 30343483     DOI: 10.1007/s00228-018-2578-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  43 in total

1.  Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.

Authors:  Donna M Fick; James W Cooper; William E Wade; Jennifer L Waller; J Ross Maclean; Mark H Beers
Journal:  Arch Intern Med       Date:  2003 Dec 8-22

2.  Making psychological theory useful for implementing evidence based practice: a consensus approach.

Authors:  S Michie; M Johnston; C Abraham; R Lawton; D Parker; A Walker
Journal:  Qual Saf Health Care       Date:  2005-02

3.  Three approaches to qualitative content analysis.

Authors:  Hsiu-Fang Hsieh; Sarah E Shannon
Journal:  Qual Health Res       Date:  2005-11

Review 4.  Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine.

Authors:  M H Beers; J G Ouslander; I Rollingher; D B Reuben; J Brooks; J C Beck
Journal:  Arch Intern Med       Date:  1991-09

5.  What is an adequate sample size? Operationalising data saturation for theory-based interview studies.

Authors:  Jill J Francis; Marie Johnston; Clare Robertson; Liz Glidewell; Vikki Entwistle; Martin P Eccles; Jeremy M Grimshaw
Journal:  Psychol Health       Date:  2010-12

6.  Potentially inappropriate prescribing in an Irish elderly population in primary care.

Authors:  Cristín Ryan; Denis O'Mahony; Julia Kennedy; Peter Weedle; Stephen Byrne
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

7.  STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation.

Authors:  P Gallagher; C Ryan; S Byrne; J Kennedy; D O'Mahony
Journal:  Int J Clin Pharmacol Ther       Date:  2008-02       Impact factor: 1.366

8.  Pharmacist-based medication review reduces potential drug-related problems in the elderly: the SMOG controlled trial.

Authors:  Thijs H A M Vinks; Toine C G Egberts; Ton M de Lange; Fred H P de Koning
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

9.  Referral of people with osteoarthritis to self-management programmes: barriers and enablers identified by general practitioners.

Authors:  Veronica J Pitt; Denise O'connor; Sally Green
Journal:  Disabil Rehabil       Date:  2008       Impact factor: 3.033

10.  IMPLEmenting a clinical practice guideline for acute low back pain evidence-based manageMENT in general practice (IMPLEMENT): cluster randomised controlled trial study protocol.

Authors:  Joanne E McKenzie; Simon D French; Denise A O'Connor; Jeremy M Grimshaw; Duncan Mortimer; Susan Michie; Jill Francis; Neil Spike; Peter Schattner; Peter M Kent; Rachelle Buchbinder; Sally E Green
Journal:  Implement Sci       Date:  2008-02-22       Impact factor: 7.327

View more
  4 in total

1.  Barriers and facilitators to deprescribing in primary care: a systematic review.

Authors:  Alison Jayne Doherty; Paul Boland; Janet Reed; Andrew J Clegg; Anne-Marie Stephani; Nefyn Howard Williams; Beth Shaw; Lynn Hedgecoe; Ruaraidh Hill; Lauren Walker
Journal:  BJGP Open       Date:  2020-08-25

Review 2.  Factors associated with potentially inappropriate prescriptions and barriers to medicines optimisation among older adults in primary care settings: a systematic review.

Authors:  Zhijie Xu; Xujian Liang; Yue Zhu; Yiting Lu; Yuanqu Ye; Lizheng Fang; Yi Qian
Journal:  Fam Med Community Health       Date:  2021-11

Review 3.  A narrative review of evidence to guide deprescribing among older adults.

Authors:  Kenya Ie; Shuichi Aoshima; Taku Yabuki; Steven M Albert
Journal:  J Gen Fam Med       Date:  2021-05-28

Review 4.  Using theories and frameworks to understand how to reduce low-value healthcare: a scoping review.

Authors:  Gillian Parker; Nida Shahid; Tim Rappon; Monika Kastner; Karen Born; Whitney Berta
Journal:  Implement Sci       Date:  2022-01-20       Impact factor: 7.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.